| 货号 | 16808-25mg |
| 描述 | Dibenzylfluorescein is a fluorogenic probe that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19).1,2,3 Dibenzylfluorescein is dealkylated by these CYP isoforms to produce fluorescein benzyl ether, which is further hydrolyzed to fluorescein by the addition of base (typically 2 M NaOH).3 Dibenzylfluorescein is typically used near its apparent Km value of 0.87-1.9 µM.1,2,3 The fluorescence of fluorescein is evaluated using excitation/emission wavelengths of 485/538 nm. Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease.1,4 |
| 别名 | DBF;NSC 645658; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Stresser, D.M.,Blanchard, A.P.,Turner, S.D., et al. Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates. Drug Metabolism and Disposition 28(12), 1440-1448 (2000). 2.Donato, M.T.,Jiménez, N.,Castell, J.V., et al. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metabolism and Disposition 32(7), 699-706 (2004). 3.Salminen, K.A.,Leppänen, J.,Venäläinen, J.I., et al. Simple, direct, and informative method for the assessment of CYP2C19 enzyme inactivation kinetics. Drug Metabolism and Disposition 39(3), 412-418 (2011). 4.Moutinho, D.,Marohnic, C.C.,Panda, S.P., et al. Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system. Drug Metabolism and Disposition 40(4), 754-760 (2012). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 512.6 |
| 分子式 | C34H24O5 |
| CAS号 | 97744-44-0 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |